Cost effectiveness of screening immigrants for hepatitis B

Liver International

Volumn 31, Issue 8, 2011, Pages 1179-1190

  Wong, William W L ^a,b   Woo, Gloria ^a,b   Jenny Heathcote, E ^c,d   Krahn, Murray ^a,b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Cost effectiveness analysis; Hepatitis B; Immigrants; Screening

Indexed keywords

ENTECAVIR; HEPATITIS B VACCINE; TENOFOVIR;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CANADA; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEPATITIS B; HUMAN; IMMIGRANT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PATIENT COMPLIANCE; QUALITY OF LIFE; SCREENING;

ADULT; AGED; ANTIVIRAL AGENTS; CANADA; COST-BENEFIT ANALYSIS; EMIGRANTS AND IMMIGRANTS; HEALTH CARE COSTS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; LIVER TRANSPLANTATION; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; MODELS, ECONOMIC; PREDICTIVE VALUE OF TESTS; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; YOUNG ADULT;

EID: 79961207009     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02559.x     Document Type: Article

References (70)

1. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009; 29(Suppl. 1): 100-7.
2. Statistics Canada. CANSIM Table 051-0006. Immigrants to Canada, by Country of Last Permanent Residence, Quarterly (persons). Ottawa, Ontario, Canada: Statistics Canada, 2009.
3. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-7.
4. Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol 2007; 21(Suppl. C): 5C-24C.
5. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53: 744-9.
6. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
7. Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat 2007; 14: 147-52.
8. Craxi A, Colombo P, D'Amico G, et al. Hepatitis B infection and liver cirrhosis: a reappraisal from the Mediterranean area. Ann Ist Super Sanita 1987; 24: 257-65.
9. D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986; 31: 468-75.
10. Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995; 21: 77-82.
11. Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002; 97: 2886-95.
12. Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 2007; 147: 460-9.
13. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
14. Jacobs RJ, Saab S, Meyerhoff AS. The cost effectiveness of hepatitis immunization for US college students. J Am Coll Health 2003; 51: 227-36.
15. Kanwal F, Farid M, Martin P, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006; 101: 2076-89.
16. Kanwal F, Gralnek IM, Martin P, et al. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005; 142: 821-31.
17. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493-6.
18. Liaw YF, Tai DI, Chu CM, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 1986; 90: 263-7.
19. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-5.
20. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
21. Margolis HS, Coleman PJ, Brown RE, et al. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995; 274: 1201-8.
22. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759-68.
23. Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Risk of Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B (CHB) Patients With or Without Cirrhosis Treated With Oral Antivirals: Results of the Nationwide HEPNET. Greece Cohort Study. Boston, MA, USA: AASLD, 2009.
24. Public Health Agency of Canada. Notifiable diseases online. Ottawa, ON, Canada: Public Health Agency of Canada, 2004. Available at.
25. Pisu M, Meltzer MI, Lyerla R. Cost-effectiveness of hepatitis B vaccination of prison inmates. Vaccine 2002; 21: 312-21.
26. Veenstra DL, Spackman DE, Di Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Aliment Pharmacol Ther 2008; 27: 1240-52.
27. Veenstra DL, Sullivan SD, Clarke L, et al. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2007; 25: 963-77.
28. Wen WH, Chang MH, Hsu HY, Ni YH, Chen HL. The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection. J Pediatr 2004; 144: 397-9.
29. Yuen MF, Yuan HJ, Hui CK, et al. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut 2003; 52: 416-9.
30. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and Entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and bayesian meta-analyses. Gastroenterology 2010; 139: 1218-29.
31. Welch S, Chiang B, Shadday P, Brosgart CL. Estimated prevalence of chronic hepatitis B (CHB) in foreign-born (FB) persons living in the United States (U.S.) by country/region of origin. 59th Annual Meeting of the American Association for the Study of Liver Diseases 2008; San Francisco, CA, USA, 2008.
32. World Health Organization. WHO Statistical Information System. Geneva, Switzerland: World Health Organization, 2009. Available at.
33. Hutton DW, So SK, Brandeau ML. Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology 2010; 51: 405-14.
34. Canadian Institute for Health Information. Health Care in Canada. Ottawa, ON, Canada: Canadian Institute for Health Information, 2004.
35. Gagnon YM, Levy AR, Iloeje UH, Briggs AH. Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection. J Clin Gastroenterol 2004; 38(Suppl. 3): S179-86.
36. Canadian Agency for Drugs and Technologies in Health. Common Drug Review Drug Database. Ottawa, ON, Canada: Canadian Agency for Drugs and Technologies in Health, 2009. Available at.
37. Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies, 3rd edn. Canada, Ottawa, ON, Canada: Canadian Agency for Drugs and Technologies in Health, 2006.
38. Organisation for Economic Co-Operation and Development. OECD iLibrary: PPPs and Exchange Rates. Paris, France: Organisation for Economic Co-Operation and Development, 2009. Available at.
39. Statistics Canada. CANSIM Table 326-0021. Consumer price index (CPI), 2005 basket content, annual (2002=100). Ottawa, ON, Canada: Statistics Canada, 2009.
40. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006; 26: 142-52.
41. Fattovich G. Natural history of hepatitis B. J Hepatol 2003; 39(Suppl. 1): S50-8.
42. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294-8.
43. Villeneuve JP. The natural history of chronic hepatitis B virus infection. J Clin Virol 2005; 34(Suppl. 1): S139-42.
44. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-52.
45. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
46. Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010; 138: 1747-54.
47. Chu CM, Liaw YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2009; 104: 1693-9.
48. Gigi E, Lalla T, Orphanou E, et al. Long term follow-up of a large cohort of inactive HBsAg (+)/HBeAg (-)/anti-HBe (+) carriers in Greece. J Gastrointest Liver Dis 2007; 16: 19-22.
49. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146: 473-81.
50. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008; 26: 733-44.
51. World Health Organization. Choosing Interventions that are Cost Effective (WHOCHOICE). Geneva, Switzerland: World Health Organization, 2005.
52. World Hepatitis Alliance. Viral Hepatitis: Global Policy. Geneva, Switzerland: World Hepatitis Alliance, 2010.
53. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26: 6266-73.
54. Public health Agency of Canada. Canada Communicable Disease Report. Ottawa, ON, Canada: Public Health Agency of Canada, 1995.
55. Public health Agency of Canada. Canadian Immunization Guide. Ottawa, ON, Canada: Public health Agency of Canada, 2006.
56. Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57(RR-8): 1-20.
57. Alderman EM, Shapiro A, Spigland I, Bashir M, Fox AS. Is prevaccination screening for hepatitis B among sexually active adolescents cost-effective? Clin Infect Dis 1998; 26: 1459-60.
58. Blostein J, Clark PA. Cost-effectiveness of preimmunization hepatitis B screening in high-risk adolescents. Public Health Rep 2001; 116: 165-8.
59. Veldhuijzen IK, Toy M, Hahne SJ, et al. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology 2010; 138: 522-30.
60. Tilson L, Thornton L, O'Flanagan D, Johnson H, Barry M. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Public Health 2008; 18: 275-82.
61. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
62. World Health Organization. Hepatitis B. Geneva, Switzerland: World Health Organization, 2002.
63. John M. Hepatitis B immunization and postimmunization serology. J Can Dent Assoc 2000; 66: 551-2.
64. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
65. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51: 422-30.
66. Ren FY, Piao DM, Piao XX. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol 2007; 13: 4264-7.
67. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
68. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
69. Buti M, Brosa M, Casado MA, Rueda M, Esteban R. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 2009; 51: 640-6.
70. Ontario Ministry of Health and Long-Term Care. Schedule of Laboratory Fees. Toronto, ON, Canada: Ontario Ministry of Health and Long-Term Care, 1999. Available at.